In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guidelines” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum.
Rapid Update v2.3 Summary
The information below provides an overview of update v2.3 to the "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer" published in Journal for ImmunoTherapy of Cancer (JITC).
- Based on the voluntary withdrawal by the manufacturer of the atezolizumab indication for the treatment of cisplatin- and platinum-ineligible patients with mUC, the Urothelial Cancer CPG has been updated in the "Diagnostic tests and biomarkers for urothelial cancer immunotherapy" and "Advanced/metastatic urothelial carcinoma" sections as well as within the mUC treatment algorithm.
- Based on the approval of nadofaragene firadenovec for the treatment of BCG-unresponsive NMIBC with CIS with or without papillary tumors, the Urothelial Cancer CPG has been updated in the "Non-muscle invasive bladder cancer section" including the NMIBC treatment algorithm.
- Based on the approval of Enfortumab vedotin with pembrolizumab for the treatment of patients with locally advanced or metastatic Urothelial Carcinoma who are ineligible for cisplatin-containing chemotherapy, the Urothelial Cancer CPG has been updated in the "Advanced/metastatic Urothelial Carcinoma" section and the mUC treatment algorithm.
How to View the Living Guideline Rapid Update
Through the use of an innovative technology, rapid updates are swiftly integrated into our existing published guidelines in a clear and concise manner. An overlay system highlights affected content and provides new text reflecting the updated Expert Panel guidance as well as important supporting information, data, and references, as applicable. These rapid updates show the progression of the changes by using a version numbering system that accompanies each new posted update.
- View Update v2.3 as an overlay to the original publication in JITC
For More Information
- SITC Urothelial Cancer CPG – Overview of all available updates and companion guideline educational offerings for this guideline
- SITC Guidelines Program – Listing of all published guidelines in the SITC CPG catalogue and more about the SITC Living Guidelines rapid update
- Follow us on social media – #SITCGuidelines on “X” and LinkedIn
- Questions – Contact a member of the SITC guideline development staff at scientificresources@sitcancer.org